{"id":36063,"date":"2025-06-26T15:22:52","date_gmt":"2025-06-26T07:22:52","guid":{"rendered":"https:\/\/flcube.com\/?p=36063"},"modified":"2025-06-26T15:22:53","modified_gmt":"2025-06-26T07:22:53","slug":"gilead-signs-licensing-pact-with-kymera-therapeutics-for-cdk2-targeted-mgd","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=36063","title":{"rendered":"Gilead Signs Licensing Pact With Kymera Therapeutics for CDK2-Targeted MGD"},"content":{"rendered":"\n

US major Gilead Sciences, Inc. (NASDAQ: GILD<\/a>) this week entered into an exclusive option and licensing agreement with compatriot firm Kymera Therapeutics, Inc. (NASDAQ: KYMR<\/a>). The collaboration aims to accelerate development and commercialization of novel molecular glue degrader (MGD) therapies targeting cyclin-dependent kinase 2 (CDK2).<\/p>\n\n\n\n

Financial Terms<\/strong>
Under the agreement, Kymera is eligible to receive up to USD 750 million in payments, including up to USD 85 million upfront and option exercise fees. Additionally, Kymera will receive tiered royalties ranging from high-single-digit to mid-teens percentages on net sales.<\/p>\n\n\n\n

Research and Development Roles<\/strong>
Kymera will lead all research activities for the CDK2 program. Gilead, upon exercising its option, will gain exclusive global rights to develop, manufacture, and commercialize any resulting products.<\/p>\n\n\n\n

Innovation in Therapeutic Approach<\/strong>
CDK2-targeting molecular glue degraders represent a next-generation therapeutic approach. Unlike traditional inhibitors that merely block CDK2 activity, these degraders promote complete degradation of CDK2. This method avoids off-target effects often seen with conventional CDK2 inhibitors, which can disrupt related proteins. The innovative approach offers a more precise and potentially safer treatment for CDK2-dependent tumors, including certain breast cancers and other solid tumors.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US major Gilead Sciences, Inc. (NASDAQ: GILD) this week entered into an exclusive option and…<\/p>\n","protected":false},"author":1,"featured_media":36064,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[226,548,1025,1269,70],"class_list":["post-36063","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-gilead-sciences","tag-kymera-therapeutics","tag-nasdaq-gild","tag-nasdaq-kymr","tag-tpd"],"yoast_head":"\nGilead Signs Licensing Pact With Kymera Therapeutics for CDK2-Targeted MGD - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US major Gilead Sciences, Inc. (NASDAQ: GILD) this week entered into an exclusive option and licensing agreement with compatriot firm Kymera Therapeutics, Inc. (NASDAQ: KYMR). The collaboration aims to accelerate development and commercialization of novel molecular glue degrader (MGD) therapies targeting cyclin-dependent kinase 2 (CDK2).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=36063\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead Signs Licensing Pact With Kymera Therapeutics for CDK2-Targeted MGD\" \/>\n<meta property=\"og:description\" content=\"US major Gilead Sciences, Inc. (NASDAQ: GILD) this week entered into an exclusive option and licensing agreement with compatriot firm Kymera Therapeutics, Inc. (NASDAQ: KYMR). The collaboration aims to accelerate development and commercialization of novel molecular glue degrader (MGD) therapies targeting cyclin-dependent kinase 2 (CDK2).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=36063\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-26T07:22:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-26T07:22:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2605.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36063#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36063\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gilead Signs Licensing Pact With Kymera Therapeutics for CDK2-Targeted MGD\",\"datePublished\":\"2025-06-26T07:22:52+00:00\",\"dateModified\":\"2025-06-26T07:22:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36063\"},\"wordCount\":200,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36063#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2605.webp\",\"keywords\":[\"Gilead Sciences\",\"Kymera Therapeutics\",\"NASDAQ: GILD\",\"NASDAQ: KYMR\",\"TPD\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36063#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36063\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=36063\",\"name\":\"Gilead Signs Licensing Pact With Kymera Therapeutics for CDK2-Targeted MGD - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36063#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36063#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2605.webp\",\"datePublished\":\"2025-06-26T07:22:52+00:00\",\"dateModified\":\"2025-06-26T07:22:53+00:00\",\"description\":\"US major Gilead Sciences, Inc. (NASDAQ: GILD) this week entered into an exclusive option and licensing agreement with compatriot firm Kymera Therapeutics, Inc. (NASDAQ: KYMR). The collaboration aims to accelerate development and commercialization of novel molecular glue degrader (MGD) therapies targeting cyclin-dependent kinase 2 (CDK2).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36063#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36063\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36063#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2605.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2605.webp\",\"width\":1080,\"height\":608,\"caption\":\"Gilead Signs Licensing Pact With Kymera Therapeutics for CDK2-Targeted MGD\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36063#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead Signs Licensing Pact With Kymera Therapeutics for CDK2-Targeted MGD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead Signs Licensing Pact With Kymera Therapeutics for CDK2-Targeted MGD - Insight, China's Pharmaceutical Industry","description":"US major Gilead Sciences, Inc. (NASDAQ: GILD) this week entered into an exclusive option and licensing agreement with compatriot firm Kymera Therapeutics, Inc. (NASDAQ: KYMR). The collaboration aims to accelerate development and commercialization of novel molecular glue degrader (MGD) therapies targeting cyclin-dependent kinase 2 (CDK2).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=36063","og_locale":"en_US","og_type":"article","og_title":"Gilead Signs Licensing Pact With Kymera Therapeutics for CDK2-Targeted MGD","og_description":"US major Gilead Sciences, Inc. (NASDAQ: GILD) this week entered into an exclusive option and licensing agreement with compatriot firm Kymera Therapeutics, Inc. (NASDAQ: KYMR). The collaboration aims to accelerate development and commercialization of novel molecular glue degrader (MGD) therapies targeting cyclin-dependent kinase 2 (CDK2).","og_url":"https:\/\/flcube.com\/?p=36063","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-26T07:22:52+00:00","article_modified_time":"2025-06-26T07:22:53+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2605.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=36063#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=36063"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gilead Signs Licensing Pact With Kymera Therapeutics for CDK2-Targeted MGD","datePublished":"2025-06-26T07:22:52+00:00","dateModified":"2025-06-26T07:22:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=36063"},"wordCount":200,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=36063#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2605.webp","keywords":["Gilead Sciences","Kymera Therapeutics","NASDAQ: GILD","NASDAQ: KYMR","TPD"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=36063#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=36063","url":"https:\/\/flcube.com\/?p=36063","name":"Gilead Signs Licensing Pact With Kymera Therapeutics for CDK2-Targeted MGD - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=36063#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=36063#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2605.webp","datePublished":"2025-06-26T07:22:52+00:00","dateModified":"2025-06-26T07:22:53+00:00","description":"US major Gilead Sciences, Inc. (NASDAQ: GILD) this week entered into an exclusive option and licensing agreement with compatriot firm Kymera Therapeutics, Inc. (NASDAQ: KYMR). The collaboration aims to accelerate development and commercialization of novel molecular glue degrader (MGD) therapies targeting cyclin-dependent kinase 2 (CDK2).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=36063#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=36063"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=36063#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2605.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2605.webp","width":1080,"height":608,"caption":"Gilead Signs Licensing Pact With Kymera Therapeutics for CDK2-Targeted MGD"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=36063#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gilead Signs Licensing Pact With Kymera Therapeutics for CDK2-Targeted MGD"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2605.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36063","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36063"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36063\/revisions"}],"predecessor-version":[{"id":36065,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36063\/revisions\/36065"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/36064"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36063"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36063"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36063"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}